Specific inhibition of CK2α from an anchor outside the active site

被引:50
作者
Brear, Paul [1 ]
De Fusco, Claudia [2 ]
Georgiou, Kathy Hadje [2 ]
Francis-Newton, Nicola J. [3 ]
Stubbs, Christopher J. [1 ]
Sore, Hannah F. [2 ]
Venkitaraman, Ashok R. [3 ]
Abell, Chris [2 ]
Spring, David R. [2 ]
Hyvonen, Marko [1 ]
机构
[1] Univ Cambridge, Dept Biochem, 80 Tennis Court Rd, Cambridge CB2 1GA, England
[2] Univ Cambridge, Dept Chem, Lensfield Rd, Cambridge CB2 1EW, England
[3] Univ Cambridge, Hutchison MRC Res Ctr, MRC, Canc Unit, Hills Rd, Cambridge CB2 0XZ, England
基金
英国惠康基金; 欧洲研究理事会; 英国工程与自然科学研究理事会; 英国医学研究理事会;
关键词
PROTEIN-KINASE CK2; CATALYTIC SUBUNIT; SELECTIVE INHIBITOR; CANCER-THERAPY; DESIGN; CELLS; LEUKEMIA; PRODRUGS; PATHWAY; CX-4945;
D O I
10.1039/c6sc02335e
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The development of selective inhibitors of protein kinases is challenging because of the significant conservation of the ATP binding site. Here, we describe a new mechanism by which the protein kinase CK2 alpha can be selectively inhibited using features outside the ATP site. We have identified a new binding site for small molecules on CK2 alpha adjacent to the ATP site and behind the alpha D loop, termed the aD pocket. An elaborated fragment anchored in this site has been linked with a low affinity fragment binding in the ATP site, creating a novel and selective inhibitor (CAM4066) that binds CK2 alpha with a K-d of 320 nM and shows significantly improved selectivity compared to other CK2 alpha inhibitors. CAM4066 shows target engagement in several cell lines and similar potency to clinical trial candidate CX4945. Our data demonstrate that targeting a poorly conserved, cryptic pocket allows inhibition of CK2 alpha via a novel mechanism, enabling the development of a new generation of selective CK2 alpha inhibitors.
引用
收藏
页码:6839 / 6845
页数:7
相关论文
共 36 条
[1]   Targeting CK2 for cancer therapy [J].
Ahmad, KA ;
Wang, GX ;
Slaton, J ;
Unger, G ;
Ahmed, K .
ANTI-CANCER DRUGS, 2005, 16 (10) :1037-1043
[2]   Structural and functional determinants of protein kinase CK2α: facts and open questions [J].
Battistutta, Roberto ;
Lolli, Graziano .
MOLECULAR AND CELLULAR BIOCHEMISTRY, 2011, 356 (1-2) :67-73
[3]   Unprecedented Selectivity and Structural Determinants of a New Class of Protein Kinase CK2 Inhibitors in Clinical Trials for the Treatment of Cancer [J].
Battistutta, Roberto ;
Cozza, Giorgio ;
Pierre, Fabrice ;
Papinutto, Elena ;
Lolli, Graziano ;
Sarno, Stefania ;
O'Brien, Sean E. ;
Siddiqui-Jain, Adam ;
Haddach, Mustapha ;
Anderes, Kenna ;
Ryckman, David M. ;
Meggio, Flavio ;
Pinna, Lorenzo A. .
BIOCHEMISTRY, 2011, 50 (39) :8478-8488
[4]   Design of ester prodrugs to enhance oral absorption of poorly permeable compounds: Challenges to the discovery scientist [J].
Beaumont, K ;
Webster, R ;
Gardner, I ;
Dack, K .
CURRENT DRUG METABOLISM, 2003, 4 (06) :461-485
[5]   Protein kinase CK2 inhibitors: a patent review [J].
Cozza, Giorgio ;
Pinna, Lorenzo A. ;
Moro, Stefano .
EXPERT OPINION ON THERAPEUTIC PATENTS, 2012, 22 (09) :1081-1097
[6]   Comprehensive analysis of kinase inhibitor selectivity [J].
Davis, Mindy I. ;
Hunt, Jeremy P. ;
Herrgard, Sanna ;
Ciceri, Pietro ;
Wodicka, Lisa M. ;
Pallares, Gabriel ;
Hocker, Michael ;
Treiber, Daniel K. ;
Zarrinkar, Patrick P. .
NATURE BIOTECHNOLOGY, 2011, 29 (11) :1046-U124
[7]   Pharmacological inhibition of protein kinase CK2 reverts the multidrug resistance phenotype of a CEM cell line characterized by high CK2 level [J].
Di Maira, G. ;
Brustolon, F. ;
Bertacchini, J. ;
Tosoni, K. ;
Marmiroli, S. ;
Pinna, L. A. ;
Ruzzene, M. .
ONCOGENE, 2007, 26 (48) :6915-6926
[8]   Potent and Selective CK2 Kinase Inhibitors with Effects on Wnt Pathway Signaling in Vivo [J].
Dowling, James E. ;
Alimzhanov, Marat ;
Bao, Larry ;
Chuaqui, Claudio ;
Denz, Christopher R. ;
Jenkins, Emma ;
Larsen, Nicholas A. ;
Lyne, Paul D. ;
Pontz, Timothy ;
Ye, Qing ;
Holdgate, Geoff A. ;
Snow, Lindsay ;
O'Connell, Nichole ;
Ferguson, Andrew D. .
ACS MEDICINAL CHEMISTRY LETTERS, 2016, 7 (03) :300-305
[9]   Proteomics perturbations promoted by the protein kinase CK2 inhibitor quinalizarin [J].
Franchin, Cinzia ;
Salvi, Mauro ;
Arrigoni, Giorgio ;
Pinna, Lorenzo A. .
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS, 2015, 1854 (10) :1676-1686
[10]   TF - A novel cell-permeable and selective inhibitor of human protein kinase CK2 induces apoptosis in the prostate cancer cell line LNCaP [J].
Goetz, Claudia ;
Gratz, Andreas ;
Kucklaender, Uwe ;
Jose, Joachim .
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, 2012, 1820 (07) :970-977